Prelude Therapeutics (PRLD) Competitors

Prelude Therapeutics logo
$3.32 -0.09 (-2.64%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$3.32 0.00 (-0.15%)
As of 11/17/2026 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PRLD vs. CVAC, OMER, SVRA, JBIO, and MLTX

Should you buy Prelude Therapeutics stock or one of its competitors? Prelude Therapeutics's main competitors and comparable companies include CureVac (CVAC), Omeros (OMER), Savara (SVRA), Jade Biosciences (JBIO), and MoonLake Immunotherapeutics (MLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prelude Therapeutics compare to CureVac?

Prelude Therapeutics (NASDAQ:PRLD) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CureVac has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude Therapeutics$12.14M21.82-$99.50M-$0.73N/A
CureVac$70.74M14.78$175.50M$0.726.47

Prelude Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Prelude Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Prelude Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Prelude TherapeuticsN/A -60.91% -35.51%
CureVac 199.92%-23.03%-19.09%

In the previous week, Prelude Therapeutics had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Prelude Therapeutics and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Prelude Therapeutics' score of -0.39 indicating that CureVac is being referred to more favorably in the news media.

Company Overall Sentiment
Prelude Therapeutics Neutral
CureVac Neutral

Prelude Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 163.55%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Prelude Therapeutics is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prelude Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

CureVac beats Prelude Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to Omeros?

Omeros (NASDAQ:OMER) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

In the previous week, Omeros had 19 more articles in the media than Prelude Therapeutics. MarketBeat recorded 23 mentions for Omeros and 4 mentions for Prelude Therapeutics. Omeros' average media sentiment score of 0.34 beat Prelude Therapeutics' score of -0.39 indicating that Omeros is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omeros
1 Very Positive mention(s)
5 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Neutral
Prelude Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Prelude Therapeutics' return on equity of -60.91% beat Omeros' return on equity.

Company Net Margins Return on Equity Return on Assets
OmerosN/A -261.02% 68.52%
Prelude Therapeutics N/A -60.91%-35.51%

Omeros has higher earnings, but lower revenue than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OmerosN/AN/A-$3.35M$1.2810.88
Prelude Therapeutics$12.14M21.82-$99.50M-$0.73N/A

Omeros has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Omeros presently has a consensus target price of $30.33, suggesting a potential upside of 117.91%. Prelude Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 163.55%. Given Prelude Therapeutics' higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Omeros.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Prelude Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

48.8% of Omeros shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Omeros beats Prelude Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Savara?

Prelude Therapeutics (NASDAQ:PRLD) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Prelude Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Savara has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Prelude Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 163.55%. Savara has a consensus target price of $10.29, indicating a potential upside of 129.59%. Given Prelude Therapeutics' higher probable upside, analysts plainly believe Prelude Therapeutics is more favorable than Savara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prelude Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Savara
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Prelude Therapeutics' return on equity of -60.91% beat Savara's return on equity.

Company Net Margins Return on Equity Return on Assets
Prelude TherapeuticsN/A -60.91% -35.51%
Savara N/A -96.87%-74.22%

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Prelude Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude Therapeutics$12.14M21.82-$99.50M-$0.73N/A
SavaraN/AN/A-$118.84M-$0.61N/A

In the previous week, Savara had 11 more articles in the media than Prelude Therapeutics. MarketBeat recorded 15 mentions for Savara and 4 mentions for Prelude Therapeutics. Savara's average media sentiment score of 1.10 beat Prelude Therapeutics' score of -0.39 indicating that Savara is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prelude Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Savara
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Prelude Therapeutics beats Savara on 7 of the 13 factors compared between the two stocks.

How does Prelude Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, Jade Biosciences had 10 more articles in the media than Prelude Therapeutics. MarketBeat recorded 14 mentions for Jade Biosciences and 4 mentions for Prelude Therapeutics. Jade Biosciences' average media sentiment score of 0.46 beat Prelude Therapeutics' score of -0.39 indicating that Jade Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
2 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prelude Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Prelude Therapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jade BiosciencesN/AN/A-$127.41M-$1.86N/A
Prelude Therapeutics$12.14M21.82-$99.50M-$0.73N/A

79.7% of Prelude Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Jade Biosciences presently has a consensus price target of $51.00, indicating a potential upside of 231.17%. Prelude Therapeutics has a consensus price target of $8.75, indicating a potential upside of 163.55%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Jade Biosciences is more favorable than Prelude Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Prelude Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Jade Biosciences has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Jade Biosciences' return on equity of -42.80% beat Prelude Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jade BiosciencesN/A -42.80% -40.09%
Prelude Therapeutics N/A -60.91%-35.51%

Summary

Jade Biosciences beats Prelude Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, MoonLake Immunotherapeutics had 10 more articles in the media than Prelude Therapeutics. MarketBeat recorded 14 mentions for MoonLake Immunotherapeutics and 4 mentions for Prelude Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of -0.09 beat Prelude Therapeutics' score of -0.39 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prelude Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Prelude Therapeutics' return on equity of -60.91% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -79.95% -56.40%
Prelude Therapeutics N/A -60.91%-35.51%

MoonLake Immunotherapeutics presently has a consensus price target of $31.33, suggesting a potential upside of 178.52%. Prelude Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 163.55%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Prelude Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.60
Prelude Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Prelude Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.67N/A
Prelude Therapeutics$12.14M21.82-$99.50M-$0.73N/A

MoonLake Immunotherapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Summary

MoonLake Immunotherapeutics and Prelude Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRLD vs. The Competition

MetricPrelude TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$272.13M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-5.6326.0433.0226.92
Price / Sales21.8216.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book3.054.184.463.72
Net Income-$99.50M-$24.15M$3.52B$393.10M
7 Day Performance-12.17%-7.80%-5.94%-5.76%
1 Month Performance1.84%-5.98%-4.59%-7.14%
1 Year Performance97.62%-8.10%-1.94%-7.46%

Prelude Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRLD
Prelude Therapeutics
2.4133 of 5 stars
$3.32
-2.6%
$8.75
+163.6%
+101.2%$272.13M$12.14MN/A79
CVAC
CureVac
N/A$4.66
flat
N/AN/A$1.05B$70.74M6.47880
OMER
Omeros
3.1532 of 5 stars
$13.72
-17.7%
$30.33
+121.1%
+53.3%$987.69MN/A10.66175
SVRA
Savara
2.7915 of 5 stars
$4.45
-0.5%
$10.29
+131.3%
+6.7%$982.86MN/AN/A70
JBIO
Jade Biosciences
2.7272 of 5 stars
$14.96
-2.5%
$51.00
+241.0%
+22.3%$951.65MN/AN/A55

Related Companies and Tools


This page (NASDAQ:PRLD) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners